Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis

Journal of the American Academy of Nurse Practitioners

Volumn 22, Issue 11, 2010, Pages 586-592

  Olmstead, Jill ^a  

^a St Jude Heritage Medical Group   (United States)

Author keywords

Gastroenterology; Gastrointestinal; Inflammatory bowel disease; Nurse practitioners; Ulcerative colitis

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

CHEMISTRY; DISEASE MANAGEMENT; DRUG ADMINISTRATION; HUMAN; NURSE ATTITUDE; NURSE PATIENT RELATIONSHIP; NURSE PRACTITIONER; NURSING; ORAL DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; MESALAMINE; NURSE PRACTITIONERS; NURSE'S ROLE; NURSE-PATIENT RELATIONS; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 78149338647     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2010.00558.x     Document Type: Review

References (51)

1. Ahnfelt-Ronne, I., Nielsen, O. H., Christensen, A., Langholz, E., Binder, V., & Riis, P. (1990). Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology, 98(5 Pt 1), 1162-1169.
2. Apriso product information. (2009). Retrieved March 20, 2009, from
3. Bernal, I., Domenech, E., Garcia-Planella, E., Marin, L., Manosa, M., Navarro, M., et al (2006). Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Digestive Diseases and Sciences, 51(12), 2165-2169.
4. Boville, D., Saran, M., Salem, J. K., Clough, L., Jones, R. R., Radwany, S. M., et al. (2007). An innovative role for nurse practitioners in managing chronic disease. Nursing Economics, 25(6), 359-364.
5. Brentnall, T. A. (2003). Molecular underpinnings of cancer in ulcerative colitis. Current Opinions in Gastroenterology, 19(1), 64-68.
6. Carter, M. J., Lobo, A. J., & Travis, S. P. (2004). Guidelines for the management of inflammatory bowel disease in adults. Gut, 53(Suppl. V), V1-V16.
7. Cerveny, P., Bortlik, M., Kubena, A., Vlcek, J., Lakatos, P. L., & Lukas, M. (2007). Nonadherence in inflammatory bowel disease: Results of factor analysis. Inflammatory Bowel Diseases, 13(10), 1244-1249.
8. Cooper, M. A., Lindsay, G. M., Kinn, S., & Swann, I. J. (2002). Evaluating emergency nurse practitioner services: A randomized controlled trial. Journal of Advanced Nursing, 40(6), 721-730.
9. Crohn's and Colitis Foundation of America (CCFA). (2007) What is IBD? possible complications. Retrieved May 15, 2009, from
10. Eaden, J., Abrams, K., Ekbom, A., Jackson, E., & Mayberry, J (2000). Colorectal cancer prevention in ulcerative colitis: A case-control study. Alimentary Pharmacology & Therapeutics, 14(2), 145-153.
11. Farup, P., Hinterleitner, T., Lukas, M., Hebuterne, X., Rachmilewitz, D., Campieri, M., et al. (2001). Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases, 7(3), 237-242.
12. Fox, S., & Chesla, C. (2008). Living with chronic illness: A phenomenological study of the health effects of the patient-provider relationship. Journal of the American Academy of Nurse Practitioner, 20(3), 109-117.
13. Ghosh, S., Shand, A., & Ferguson, A. (2000). Ulcerative colitis. British Medical Journal, 320(7242), 1119-1123.
14. Green, J. R., Lobo, A. J., Holdsworth, C. D., Leicester, R. J., Gibson, J. A., Kerr, G. D., et al. (1998). Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology, 114(1), 15-22.
15. Hall, N. J., Rubin, G. P., Hungin, A. P., & Dougall, A. (2007). Medication beliefs among patients with inflammatory bowel disease who report low quality of life: A qualitative study. BMC Gastroenterology, 7, 20.
16. Han, S. W., McColl, E., Barton, J. R., James, P., Steen, I. N., & Welfare, M. R. (2005). Predictors of quality of life in ulcerative colitis: The importance of symptoms and illness representations. Inflammatory Bowel Diseases, 11(1), 24-34.
17. Hanauer, S. B., Sandborn, W. J., Dallaire, C., Archambault, A., Yacyshyn, B., Yeh, C., et al. (2007). Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology, 21(12), 827-834.
18. Hanauer, S. B., Sandborn, W. J., Kornbluth, A., Katz, S., Safdi, M., Woogen, S., et al. (2005). Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial. American Journal of Gastroenterology, 100(11), 2478-2485.
19. Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H. P., & Yao, X. (2008). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews (Online), (2), CD000011.
20. Irvine, E. J. (2004). Review article: Patients' fears and unmet needs in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 20(Suppl. 4), 54-59.
21. Janke, K. H., Klump, B., Gregor, M., Meisner, C., & Haeuser, W. (2005). Determinants of life satisfaction in inflammatory bowel disease. Inflammatory Bowel Diseases, 11(3), 272-286.
22. Kaiser, G. C., Yan, F., & Polk, D. B. (1999). Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology, 116(3), 602-609.
23. Kale-Pradhan, P. B., Pradhan, R. S., & Wilhelm, S. M. (2008). Multi-matrix system mesalamine: To use or not to use. Annals of Pharmacotherapy, 42(2), 265-269.
24. Kamm, M. A., Sandborn, W. J., Gassull, M., Schreiber, S., Jackowski, L., Butler, T., et al. (2007). Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology, 132(1), 66-75.
25. Kane, S. V. (2006). Systematic review: Adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology & Therapeutics, 23(5), 577-585.
26. Kane, S. V., Brixner, D., Rubin, D. T., & Sewitch, M. J. (2008). The challenge of compliance and persistence: Focus on ulcerative colitis. Journal of Managed Care Pharmacy, 14(1 Suppl. A), s2-s12.
27. Kane, S., De Vos, M., Riley, S., Frieri, G., & Mittmann, U. (2005). Compliance issues in inflammatory bowel disease. Reviews in Gastroenterological Disorders, 5(2), 101-106.
28. Kane, S., Huo, D., Aikens, J., & Hanauer, S. (2003). Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine, 114(1), 39-43.
29. Kornbluth, A., & Sachar, D. B. (2004). Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology, 99(7), 1371-1385.
30. Larkin, H. (2003). The case for nurse practitioners. Used correctly, they can improve outcomes, lower costs and make up for reduced residents' hours. Hospitals and Health Networks, 77(8), 54-58, 2.
31. Lewis, J. D., Lichtenstein, G. R., Deren, J. J., Sands, B. E., Hanauer, S. B., Katz, J. A., et al. (2007). A randomized, placebo-controlled trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Gastroenterology, 13 (24, Suppl. 1), (Abstract 639a).
32. Lichtenstein, G. R., Kamm, M. A., Boddu, P., Gubergrits, N., Lyne, A., Butler, T., et al. (2007). Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology, 5, 95-102.
33. Lim, W. C., & Hanauer, S. B. (2004). Controversies with aminosalicylates in inflammatory bowel disease. Reviews in Gastroenterological Disorders, 4(3), 104-117.
34. Litaker, D., Mion, L., Planavsky, L., Kippes, C., Mehta, N., & Frolkis, J. (2003). Physician - nurse practitioner teams in chronic disease management: The impact on costs, clinical effectiveness, and patients' perception of care. Journal of Interprofessional Care, 17(3), 223-237.
35. Loftus, E. V., Jr. (2006). A practical perspective on ulcerative colitis: Patients' needs from aminosalicylate therapies. Inflammatory Bowel Diseases, 12(12), 1107-1113.
36. Meucci, G., Fasoli, R., Saibeni, S., Valpiani, D., Gullotta, R., Colombo, E., et al. (2006). Prognostic significance of endoscopy remission in patients with active ulcerative colitis treated with oral and topical mesalazine: Preliminary results of a prospective, multicenter study. Gastroenterology, 130 A-197 (Abstract S1302).
37. Moody, G. A., Eaden, J. A., Helyes, Z., & Mayberry, J. F. (1997). Oral or rectal administration of drugs in IBD? Alimentary Pharmacology & Therapeutics, 11(5), 999-1000.
38. National Digestive Diseases Information Clearinghouse. (2007). Ulcerative colitis. Retrieved May 15, 2009, from
39. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353(5), 487-497.
40. Prescott, P. A., & Driscoll, L. (1980). Evaluating nurse practitioner performance. Nurse Practitioner, 5(4), 28-2, passim.
41. Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., et al. (2005). Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. Journal of Experimental Medicine, 201(8), 1205-1215.
42. ®) mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: A combined analysis of two randomized, double-blind, placebo-controlled trials. Alimentary Pharmacology & Therapeutics, 26(2), 205-215.
43. Sandborn, W. J., Regula, J., Faegan, B., Belousova, E. A., Jojic, N. V., Lucas, M., et al. (2008). Efficacy and safety of delayed-release oral mesalamine at 4.8 g/D (800 mg tablet) in the treatment of moderately active ulcerative colitis: Results of the Ascend III study. Gastroenterology, 134(4 Suppl. 1), A-99 (Abstract 702).
44. Sutherland, L., & MacDonald, J. K. (2006a). Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews (Online), (2), CD000543.
45. Sutherland, L., & MacDonald, J. K. (2006b). Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews (Online), (2), CD000544.
46. Svartz, N. (1942). Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulphanilamide preparations. Acta Medica Scandinavica (110), 577-598.
47. Tenjarla, S., Romasanta, V., Zeijdner, E., Villa, R., & Moro, L. (2007). Release of 5-aminosalicylate from the MMX™ mesalamine tablet during transit through a simulated gastrointestinal tract system. Advances in Therapy, 24(4), 826-840.
48. Turnbough, L., & Wilson, L. (2007). "Take your medicine": Nonadherence issues in patients with ulcerative colitis. Gastroenterology Nursing, 30(3), 212-217.
49. Ullman, T. A. (2005). Preventing neoplastic progression in ulcerative colitis. Journal of Clinical Gastroenterology., 39(4 Suppl. 2), S66-S69.
50. Waters, B. M., Jensen, L., & Fedorak, R. N. (2005). Effects of formal education for patients with inflammatory bowel disease: A randomized controlled trial. Canadian Journal of Gastroenterology, 19(4), 235-244.
51. World Health Organization (2003). Adherence to long-term therapies. Evidence for action. Retrieved May 2009 from